WSC
VRTX icon

Wellington Shields & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Wellington Shields & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-800
Closed -$209K – 295
2022
Q1 		$209K Sell
800
-200
-20% -$47.5K 0.07% 202
2021
Q4 		$220K Sell
1,000
-200
-17% -$38.9K 0.04% 205
2021
Q3 		$218K Hold
1,200
– – 0.08% 190
2021
Q2 		$242K Buy
+1,200
New +$251K 0.08% 180

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Wellington Shields & Co's VRTX Position: Q2 2022 in Review

Wellington Shields & Co sold out of Vertex Pharmaceuticals (VRTX) in Q2 2022, closing a stake of 800 shares — an estimated $209K sold.

Wellington Shields & Co first reported a position in VRTX in Q2 2021 and held it in 4 quarters. The position peaked at $242K in Q2 2021. 1,106 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

  • Wellington Shields & Co reported no remaining Vertex Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Wellington Shields & Co sold 800 Vertex Pharmaceuticals shares in Q2 2022, an estimated $209K.
  • Wellington Shields & Co first reported a position in Vertex Pharmaceuticals in Q2 2021 and held it in 4 quarters.
  • Wellington Shields & Co's Vertex Pharmaceuticals position peaked at $242K in Q2 2021.
  • 1,106 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on Wellington Shields & Co's 13F filing for Q2 2022, filed 12 Aug 2022.